| Today’s Big NewsJun 4, 2025 |
| By Zoey Becker With the deal, Lilly can use Camurus' long-acting delivery technology on up to four of its own incretin compounds to develop injections in the cardiometabolic health space. |
|
|
|
By Nick Paul Taylor A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the Sanofi-bound biotech to stop a long-term extension trial of the TREM2 agonist. |
By James Waldron Bayer’s Vividion Therapeutics has secured the global rights from its partner Roche to the only covalent Werner helicase inhibitor to have made it into the clinic. |
Sponsored by Thermo Fisher Scientific Austin Read of Thermo Fisher Scientific discusses how combining biospecimens with real-world data is advancing diagnostics, treatment and the future of patient care. |
|
From gene therapy pipelines to early-stage VC deals, biotech leaders are seeking clarity in the chaos. That’s why companies are sharing their insights through Fierce content hubs — with weekly features right here in your inbox. See how others are shaping the narrative. 
|
|
By Darren Incorvaia Even after scrapping its lead obesity candidate due to liver toxicity, BioAge Labs is not shying away from the weight loss space. The Bay Area biotech has entered an option agreement with Chinese firm JiKang Therapeutics to potentially license a new apelin receptor (APJ) agonist nanobody. |
Sponsored by Bayer Discover how Bayer and BlueRock are redefining biotech partnerships. From breakthrough Parkinson’s therapies to a unique “arm’s-length” model, this episode of The Top Line dives into what makes their collaboration a blueprint for the future. |
By James Waldron Ascletis Pharma’s acne pill has scored a phase 3 win, leading the Chinese biotech to claim the Sagimet Biosciences drug can hold its own against FDA-approved products Seysara and doxycycline. |
Sponsored by Marken, UPS Healthcare Precision Logistics Radiopharma is revolutionizing modern medicine. Discover how precision logistics empowers faster, safer delivery of life-impacting therapies when every second counts. |
By Darren Incorvaia Protein degradation company Plexium has laid off staff as part of a realignment to support the company’s pipeline, which is mostly preclinical, Fierce Biotech has learned. |
By Noah Tong A new class-action lawsuit asserts the Department of Health and Human Services and the Department of Government Efficiency fired civil servants based on incorrect internal personnel records. |
By Andrea Park Pharmas looking to recruit younger workers should meet Gen Z where they’re at: namely, TikTok and Instagram, according to a new report from the Association of the British Pharmaceutical Industry. |
By Paige Minemyer The Trump administration's Medicaid director will depart the role as the Republicans' push to codify massive cuts to the program heats up, according to a report from Politico. |
By Dave Muoio The CMS under President Joe Biden had told hospitals that life-saving abortions fall within the requirements of the federal Emergency Medical Treatment and Labor Act (EMTALA), which preempts state law. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," we’re examining the future of tech-enabled home care and the policy decisions that could determine whether these models become permanent fixtures in the U.S. healthcare system. |
|
|---|
|
|
Whitepaper We analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
+(2)+(2).png)
